ethyl-3-phenylpropyl-H-phosphinate | 86552-54-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-3-phenylpropyl-H-phosphinate
• 英文别名: 3-[Ethoxy(oxido)phosphaniumyl]propylbenzene；3-[ethoxy(oxido)phosphaniumyl]propylbenzene
• CAS: 86552-54-7
• 化学式: C₁₁H₁₇O₂P
• 分子量: 212.229
• InChiKey: KXQRCUFTVPXAQS-UHFFFAOYSA-N

物化性质

• 沸点：
  308.4±35.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl-3-phenylpropyl-H-phosphinate 在 palladium on activated charcoal 吡啶 、 三甲基氯硅烷 、 氢气 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 53.0h， 生成 (4-Carbamimidoylphenyl) 4-[[ethoxy(3-phenylpropyl)phosphoryl]methyl]benzoate
  参考文献：
  名称：

  New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity

  摘要：

  A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00036-9
• 作为产物：
  描述：

  (3-Phenylpropyl)phosphonous acid, diethyl ester 以 水 为溶剂， 生成 ethyl-3-phenylpropyl-H-phosphinate
  参考文献：
  名称：

  Phosphonamidate compounds

  摘要：

  式中X为取代或未取代的亚胺基或氨基酸或酯。这些化合物具有血管紧张素转化酶活性，因此可用作降压剂。

  公开号：

  US04432971A1

文献信息

• Manganese-Catalyzed and Promoted Reactions of<i>H</i>-Phosphinate Esters
  作者：Henry C. Fisher、Olivier Berger、Fabien Gelat、Jean-Luc Montchamp

  DOI：10.1002/adsc.201301157

  日期：2014.4.14

  with alkenes and alkynes using catalytic manganese(II) acetate. Under stoichiometric conditions with manganese(III) acetate or with catalytic manganese(II) acetate+excess manganese(II) oxide various reactions like arylation or cyclization through radical oxidative arylation can take place. Whereas the chemistry of manganese is already well developed for the functionalization of H‐phosphonates, the present

  H-膦酸酯使用乙酸锰（II）与烯烃和炔烃反应。在化学计量条件下，用乙酸锰（III）或催化性乙酸锰（II）+过量的锰（II）进行各种反应，如芳基化或通过自由基氧化芳基化的环化反应。尽管锰的化学已经很好地用于H膦酸酯的官能化，但本方法学提供了以可接受的高收率获得官能化的次膦酸酯的空前途径。
• [EN] NEW PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DU PHOSPHORE, ANALOGUES DE SUCRES, ET COMPOSITIONS AYANT UNE ACTIVITÉ ANTICANCÉREUSE LES CONTENANT
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2009004096A1

  公开（公告）日：2009-01-08

  The invention provides new anticancer compounds of formula (1) such as defined in the present description. The invention also provides pharmaceutical compositions to be used in human or veterinary medicine, comprising at least one compound of formula (1). The present invention further relates to a compound of formula (1) such as defined in the present description, for use as a drug. The invention further relates to the use of a compound of formula (1) for manufacturing a human or animal anticancer pharmaceutical composition.

  该发明提供了新的抗癌化合物，其化学式为（1），如本说明中所定义。该发明还提供了用于人类或兽医药物的制剂，包括至少一种化合物（1）。本发明进一步涉及一种化合物，其化学式为（1），如本说明中所定义，用作药物。该发明还涉及使用化合物（1）制造人类或动物抗癌药物组合物。
• Manganese-Catalyzed and Mediated Synthesis of Arylphosphinates and Related Compounds
  作者：Olivier Berger、Jean-Luc Montchamp

  DOI：10.1021/acs.joc.9b01239

  日期：2019.7.19

  H-phosphinates and related compounds was examined. A practical catalytic process with the air as the oxidant could not be found. However, an inexpensive and robust methodology was developed, using catalytic Mn(II) as the radical initiator and excess Mn(IV) as the stoichiometric oxidant. Using these conditions, the inter- and intramolecular arylation of phosphinylidene compounds has a broad scope, including

  检查了H-次膦酸酯和相关化合物的自由基芳基化。找不到以空气为氧化剂的实际催化方法。但是，开发了一种廉价而稳健的方法，使用了催化性的Mn（II）作为自由基引发剂，而过量的Mn（IV）作为化学计量的氧化剂。使用这些条件，次膦基化合物的分子间和分子内芳基化具有广泛的范围，包括应用于合成P-杂环。完整介绍了该方法，并讨论了其局限性。
• Palladium-catalyzed phosphorus–carbon bond formation: cross-coupling reactions of alkyl phosphinates with aryl, heteroaryl, alkenyl, benzylic, and allylic halides and triflates
  作者：Karla Bravo-Altamirano、Zhihong Huang、Jean-Luc Montchamp

  DOI：10.1016/j.tet.2005.03.107

  日期：2005.6

  palladium catalysis. This full paper examines the scope and some mechanistic aspects of this phosphorus–carbon bond forming reaction. The reactions of alkenyl and allylic halides are also described for the first time. This novel cross-coupling provides a convenient access to a variety of substituted H-phosphinates.

  H-芳基次膦酸酯和相关化合物的直接形成可以使用钯催化来完成。这篇全文探讨了这种磷-碳键形成反应的范围和一些机理方面。还首次描述了烯基和烯丙基卤化物的反应。这种新颖的交叉偶联可方便地获得各种取代的H-次膦酸酯。
• Leukotriene B4 antagonist compounds and method for treatment
  申请人：——

  公开号：US20020128315A1

  公开（公告）日：2002-09-12

  Novel amidinophenol derivatives of formula (IB) 1 and processes for the preparation thereof; compositions containing a compound of formula (IB) as active ingredient useful as antagonists of leukotine B 4 and inhibitors of phospholipase A 2 and/or trypsin; methods for preventing or treating diseases induced by phospholipase A 2 and/or trypsin comprising administering to a patient a compound of formula (IB); and methods for treating diseases induced by leukotine B 4 comprising administering to a patient a compound of formula (IB) or a known amidinophenol derivative of formula (IA) 2

  公式（IB）1的新型氨基酚衍生物及其制备方法；含有公式（IB）化合物作为活性成分的组合物，用作白三烯B4的拮抗剂和磷脂酶A2和/或胰蛋白酶的抑制剂；预防或治疗由磷脂酶A2和/或胰蛋白酶引起的疾病的方法，包括向患者给予公式（IB）化合物；以及治疗由白三烯B4引起的疾病的方法，包括向患者给予公式（IB）化合物或已知的公式（IA）2的氨基酚衍生物。